VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 560 filers reported holding VALEANT PHARMACEUTICALS INTL in Q1 2015. The put-call ratio across all filers is 2.18 and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $7,571,000 | -25.2% | 325,790 | -48.8% | 0.09% | -32.8% |
| Q1 2018 | $10,125,000 | +11.9% | 635,980 | +46.0% | 0.13% | +14.9% |
| Q4 2017 | $9,052,000 | +128.5% | 435,630 | +57.6% | 0.11% | +128.0% |
| Q3 2017 | $3,962,000 | -97.3% | 276,490 | -65.9% | 0.05% | -98.0% |
| Q3 2015 | $144,731,000 | -13.9% | 811,361 | +7.2% | 2.48% | -3.3% |
| Q2 2015 | $168,081,000 | -33.7% | 756,609 | -40.7% | 2.56% | -37.1% |
| Q1 2015 | $253,412,000 | -26.9% | 1,275,861 | -47.4% | 4.08% | -25.0% |
| Q4 2014 | $346,865,000 | +4.6% | 2,423,766 | -4.1% | 5.44% | +12.1% |
| Q3 2014 | $331,660,000 | +0.2% | 2,527,896 | -3.7% | 4.85% | +2.1% |
| Q2 2014 | $331,067,000 | +3.7% | 2,625,014 | +8.4% | 4.75% | +6.4% |
| Q1 2014 | $319,263,000 | +66.4% | 2,421,778 | +48.2% | 4.47% | +80.2% |
| Q4 2013 | $191,813,000 | +296.8% | 1,633,838 | +190.9% | 2.48% | +278.9% |
| Q2 2013 | $48,343,000 | – | 561,601 | – | 0.65% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |